Relation has announced two strategic collaborations with GSK, focusing on the discovery and validation of therapeutics that target fibrotic diseases and osteoarthritis. Relation will obtain a $45m ...

Relation announced two multi-program strategic collaborations with GSK (GSK). The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases ...

Relation Therapeutics is teaming with GSK on two multi-program strategic collaborations. The partnership announced on Tuesday morning will prioritize the development of novel disease targets for ...

GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in ...

Relation Therapeutics and GSK signed two contracts to discover and develop new therapeutic targets to treat osteoarthritis and fibrotic disease. The U.K. biotech will receive a total upfront ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...

London, UK, December 10, 2024 - Relation, an industry leader in deploying computation and experimentation to drug discovery, today announced two multi-program strategic collaborations with GSK. The ...